Skip to content

Hip Denervation and Intra-articular Hydration in Damaged Hip in Axial Spondyloarthritis Patients

Hip Denervation and Intra-articular Hydration in Damaged Hip in Axial Spondyloarthritis Patients

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05219084
Enrollment
60
Registered
2022-02-01
Start date
2021-12-01
Completion date
2022-04-15
Last updated
2022-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Axial SpA According to ASAS Criteria, Patients With Unilateral or Bilater Hip Damage According to BASRI Score, Age > 18

Brief summary

Background: The hip joint is frequently affected in axial spondyloarthritis (SpA) of adults with destructive effects in untreated patients. About 35% of axial SpA patients had either unilateral or bilateral hip arthritis. Destruction is more common with early-onset, active disease, or enthesitis. Objectives: The aim of this study is to evaluate the effect of hip denervation (HD) and intra-articular hydration (IAH) on pain, function score, hip mobility scores in a cohort of axial SpA patients with grade 3 and 4 hip BASRI scores.

Interventions

DRUGhip denervation

Lidocaine 2% 2ml was injected into each genicular nerve

DRUGintra-articular hydration

10 ml; of normal; saline were injected inside the hip joint

hip denervation and intra-articular hydration were conducted together

DRUGControl group

Normal; saline was injected subcutaneously

Sponsors

Suez Canal University
CollaboratorOTHER
Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age 18 or more * Axial; SpA fulfilled ASA criteria * BASRI score grade 3 or 4 for one hip at least

Exclusion criteria

* patients younger than 18 * Axial; SpA with normal hip or hip involvement less than 3 on BASRI score

Design outcomes

Primary

MeasureTime frameDescription
Change in Harris functional hip scoreBaseline, after 4 weeks and after 12 weeksPain receives 44 points, function 47 points, range of motion 5 points, and deformity 4 points. Function is subdivided into activities of daily living (14 points) and gait (33 points). The higher the HHS, the less dysfunction. A total score of \<70 is considered a poor result; 70-80 is considered fair, 80-90 is good, and 90-100 is an excellent result
Change in visual analogue scaleBaseline , after 4 weeks and after 12 weeks0 means no pain, 100 means the highest degree of pain
Change in range of motion of the hipBaseline, after 4 weeks and after 12 weekship flexion, extension , internal; rotation , external; rotation , abduction , and adduction all were recopreded
Change in semiquantitative tenderness scoreBaseline, after 4 weeks and after 12 weeksa score from 0-3, 90 means no tenderness and 3 means maximum tenderness

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026